Since 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need.
In just over 20 years, Gilead has become a leading biopharmaceutical company with a portfolio of 14 marketed products, a growing pipeline of investigational drugs and approximately 4,200 employees in offices across four continents.
Gilead�s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular/metabolic and respiratory conditions.
Gilead Sciences, Inc. (Nasdaq:GILD) recently announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company�s Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera�, combining Gilead�s Truvada� (emtricitabine and tenofovir disoproxil (as fumarate)) with Tibotec Pharmaceuticals� non-nucleoside reverse transcriptase inhibitor Edurant� (rilpivirine (as hydrochloride)) for the treatment of HIV-1 infection in antiretroviral-na�ve adults with a viral load less than or equal to 100,000 HIV-1 RNA copies/mL.
The CHMP�s positive recommendation will be reviewed by the European Commission, which has the authority to approve medicinal products for use in the 27 countries of the European Union (EU). Gilead expects the European Commission to issue its decision on the marketing authorization for the Eviplera single-tablet regimen later this year.
�There is a need for the simplification of treatment regimens featuring co-formulated, fixed-dose medicines as patients stay on therapy longer,� said John C. Martin, PhD, Chairman and Chief Executive Officer, Gilead Sciences. �We are pleased to move one step closer to making this potentially important new simplified treatment option available to physicians and patients in Europe.�
The regulatory filing for the Eviplera single-tablet regimen is supported by 48-week data from two Phase 3 double-blind, active controlled, randomized studies (ECHO and THRIVE) conducted by Tibotec evaluating the safety and efficacy of rilpivirine compared to efavirenz in treatment-na�ve HIV-1 infected adults. Both arms of the studies were administered with a background regimen, in which the majority of patients in the rilpivirine arm received Truvada. A bioequivalence study conducted by Gilead demonstrated that the co-formulated single-tablet regimen achieved the same levels of medication in the blood as emtricitabine plus rilpivirine plus tenofovir disoproxil fumarate.
More about GILD at www.gilead.com
The main benefits of Internet marketing is that it can allow a business to reach a larger audience than other marketing methods. Websites are accessible to anyone in the world with an Internet connection so long as they are not blocked by network administrators (some countries and workplaces block certain websites). This means that a website devoted to promoting a company or ads placed on popular websites can potentially be seen by millions of customers across the world.
Crown Equity Holdings Inc. (OTC:CRWE), together with its digital network, currently provides electronic media services specializing in online publishing, which brings together targeted audiences and advertisers.
Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.
CRWE�s digital network is designed, on behalf of its clients, to bring together targeted high-income audiences and advertisers on its financial websites that include, among others, DrStockPick.com, PennyOmega.com, BestOtc.com, CRWEFinance.com, CRWESelect.com, CRWEPicks.com and StockHotTips.com.
Crown Equity Holdings Inc. is pleased to announce that it has entered into a joint venture to deploy VoIP (Voice over Internet Protocol) technology delivering voice, video and data services to residential and commercial customers. The joint venture company is Crown Tele Services Inc. which was a wholly-owned subsidiary of Crown Equity Holdings Inc. Crown Equity Holdings Inc. will own fifty percent (50%) interest in the joint venture.
Commenting on the joint venture, Kenneth Bosket, President of Crown Equity Holdings Inc., said: �We are excited to deliver VoIP communications solutions specifically designed to meet the business and residential market needs in this fast-growing global market.�
For more information, please visit: http://www.crownequityholdings.com
Cimarex Energy Co. (NYSE:XEC) has declared a regular cash dividend on its common stock of 10 cents-per-share. The dividend is payable on December 1, 2011 to stockholders of record on November 15, 2011. Denver-based Cimarex Energy Co. is an independent oil and gas exploration and production company with principal operations in the Mid-Continent, Permian Basin and Gulf Coast areas of the U.S.
Cimarex Energy Co. operates as an independent oil and gas exploration and production company primarily in Texas, Oklahoma, New Mexico, Kansas, and Wyoming.
Newpark Resources, Inc. (NYSE:NR) announced that it will release its third quarter 2011 results on Thursday, October 27, 2011 after the market closes. In conjunction with the release, the Company has scheduled a conference call, which will be broadcast live over the Internet, for Friday, October 28, 2011 at 10:00 a.m. Eastern / 9:00 a.m. Central. Newpark Resources Third Quarter 2011 Earnings Conference Call. Friday, October 28, 2011 at 10:00 a.m. Eastern / 9:00 a.m. Central. Live via phone — By dialing 480-629-9771 and asking for them. Newpark Resources call at least 10 minutes prior to the start time, or Live over the Internet By logging onto the web at the address, http://www.newpark.com.
Newpark Resources, Inc., together with its subsidiaries, provides fluids management, waste disposal, and well site preparation products and services primarily to the oil and gas exploration and production industry in the United States and internationally.
Carpenter Technology Corporation (NYSE:CRS) announced a major expansion of its Carpenter Powder Products facility in Sweden (CPP AB). Located in Torsh�lla, CPP AB is a joint venture operation with Sandvik Materials Technology and is one of three powder metal manufacturing sites associated with Carpenter Powder Products (CPP), a subsidiary of Carpenter Technology Corporation. CPP is the leading global producer of gas atomized powder metal products serving a variety of industries and has additional locations in Pennsylvania and Rhode Island.
Carpenter Technology Corporation engages in the manufacturing, fabrication, and distribution of specialty metals. The company Advanced Metals Operations segment offers metal alloys, stainless steels, and titanium in the form of small bars and rods, wire, narrow strip, and powder.
No comments :
Post a Comment